RenaGel polymer-based phosphate binder data

University researchers reported positive data from an open-label, Phase IIb dose titration study of RenaGel for the control of elevated phosphorus levels in chronic kidney failure patients. As discussed at the Harvard Medical School's Nephrology-1996 seminar in Boston, RenaGel was well tolerated, with no serious drug-related adverse events. RenaGel controlled serum phosphorus levels as well as currently used phosphate binders, but without the risk of hypercalcemia those entail.

The 48-patient study was designed to follow the expected treatment regimen for RenaGel. Chronic dialysis patients whose phosphate levels were being treated with calcium- and/or aluminum-based phosphate binders were enrolled. ...